RSC Advances



PAPER

View Article Online



Cite this: RSC Adv., 2021, 11, 36250

Facile synthesis and nematicidal activity evaluation of thiophosphinyl amide [(Pz)2P(S)NHR] and thiophosphonyl diamide [(Pz)P(S)(NHR)₂] (Pz = 1,3,5-trimethylpyrazole, R = biphenyl derivatives)†

Xiao Chen, D Xiaogang Lu, D Haibo Liu, Hongmei Wang * and Chengxin Pei*

A series of thiophosphinyl amide [(Pz)₂P(S)NHR] and thiophosphonyl diamide [PzP(S)(NHR)₂] compounds, where Pz = 1.3.5-trimethylpyrazole and N(H)R = derivatives of 2-aminobiphenyl, were synthesized via a facile two-step process. Reaction of pyrazolyl substituted bromophosphine with 2-aminobiphenyl derivatives and further reaction with elemental sulphur affords the corresponding thiophosphinyl amide and thiophosphonyl diamide. The intermediate species was used without prior purification for reaction with sulphur to yield the target compounds. The nematicidal activity evaluation suggests that some compounds could manifest moderate nematicidal activity towards Meloidogyne incogita, which is higher than that of their amide analogue bixafen.

Received 17th August 2021 Accepted 27th October 2021

DOI: 10.1039/d1ra06232h

rsc.li/rsc-advances

Introduction

The biological activities of organophosphorus compounds are well documented and their action mode is in part related to the presence of the phosphate group in nucleotides and cell membranes.1-4 In the medical field, the phosphate containing drug remdesivir has been developed,5,6 while in the agricultural industry this approach has also garnered success, as exemplified by the pesticide Imicyafos.7-9 It should be noted that compared with the highly investigated small molecule organophosphorus compounds (like phosphate esters), 4,10-13 there is comparatively little research on the synthesis and bio-activity of their pyrazole derivatives,14-20 an area of research that is particularly relevant since the bio-activity of such compounds is well documented.21-24 Indeed, some of the phosphonyl pyrazole derivatives have been shown to possess biological activity, like antimicrobial, anticancer and antioxidant activities. 25-29

prompted us to investigate agricultural pesticides, in particular those that act as a succinate dehydrogenase inhibitor (SDHI). To date, 23 SDHI compounds have been listed by the Fungicide Resistance Action Committee (FRAC) (selected SDHIs are listed in Fig. 1). Previous investigation suggests that fluopyram, one of these SDHI, could inhibit the growth of Meloidogyne incognita, with a 2 h EC_{50} value of 5.18 mg mL $^{-1}$.30 This nematicide activity was higher than those of the other tested SDHIs, like boscalid,

Our primary interest in the bioactivity of organophosphorus

compounds, we believe that a successful approach could involve the synergistic combination of the basic molecular scaffold of existing SDHIs with the biologically active organophosphorus moiety. Herein, we report the facile synthesis of 16 novel thiophosphinyl amides and thiophosphonyl diamides, together

flutolanil, penthiopyrad and benzovindiflupyr. 30 In this fertile

area, a number of novel SDHI-based compounds and their nematicidal activity are currently under investigation, some of

which will be released into the market soon, such as the new nematicide named cyclobutrifluram, developed by Syngenta.31

The promising nematicidal activity of fluopyram and cyclo-

butrifluram suggests that further research of SDHI-based compounds as effective nematicidal agents is warranted.32,33

Considering the potential bio-activity of organophosphorus

Fig. 1 Molecular structures of selected SDHIs (boscalid, pyraziflumid, bixafen and fluxapyroxad).

State Key Laboratory of NBC Protection for Civilian, Beijing 102205, China. E-mail: wanghongmei@dicp.ac.cn; chengxin.ricd@yahoo.com.cn

 $[\]dagger$ Electronic supplementary information (ESI) available: $^1\!H,~^{13}\!C$ and $^{31}\!P$ NMR spectra, IR spectra and MS spectra. See DOI: 10.1039/d1ra06232h

with data on their nematicidal activity towards Meloidogyne incognita.

Results and discussion

Target compounds were designed by combination of specific structural features of certain SDHIs and the biologically active organophosphorus moiety, which should act synergistically to promote their biological activity. Among the 23 SDHIs listed by FRAC, 12 contain a 1-methylpyrazole group, which includes isoflucypram, penflufen, pydiflumetofen, fluxapyroxad, and sedaxane, underscoring the importance of pyrazole groups for biological activity. Furthermore, the SDHIs of acaricide pyflubumide similarly possess a 1,3,5-trimethylpyrazole group.^{34,35}

Based on these precedents, we decided to incorporate the 1,3,5-trimethylpyrazole moiety in our novel thiophosphine based nematicides. A C-5 methyl group should prevent migration of a phosphine group between C-2 and C-3, a process that has been widely observed for other pyrazole derivatives.^{36,37} In addition, some analogues of 2-aminobiphenyl have been employed as pesticidal agents.

The 1,3,5-trimethylpyrazole substituted bromophosphine (1 and 2) were prepared following a previously published protocol. ¹⁵ Due to the π -rich character of a pyrazol ring, PBr₃ can directly react with 1,3,5-trimethylpyrazole in the presence of pyridine, which acts as both a solvent and an acid acceptor, leading to the corresponding phosphorylation products 1 and 2. After a standard reaction of 1 (or 2) with the corresponding analogues of 2-aminobiphenyl, in the presence of triethylamine, the resulting crude phosphinylamine (phosphonyldiamine) directly reacted with stoichiometric amount of S₈, giving the desired compounds 1a-1h (or 2a-2h) (Fig. 2). Tedious

purification procedures such as column chromatography could be avoided, and crystallization proceeded smoothly after a simple workup procedure. The crude products 1a-1h were directly isolated after the removal of a violet filtrate, followed by washing with petroleum ether. Spectroscopically pure compounds were obtained after crystallization from ethyl acetate/petroleum ether (v/v = 1:1), affording products in moderate to high yields. To obtain the purified products 2a-2h, petroleum ether was added directly to a partially concentrated crude mixture, giving two separate layers, with the interface acting as a vehicle for slow crystallization of the products obtained in moderate yields.

In the 1 H NMR spectra, the –NH signals at around 5 ppm were observed as doublets in all compounds, which indicated the existence of $^2J_{\rm PH}$ coupling and the formation of P–N bonds. IR spectroscopy analysis confirmed the presence of a secondary amine with a single sharp N–H stretch absorption band $v({\rm NH})$ observed at around 3380 cm $^{-1}$. Taken together, the NMR and IR data both confirmed the presence of a secondary amide where the nitrogen was bound to a phosphorus atom. Meanwhile, the single doublet indicated the presence of symmetric –NH groups in **1a–1h** in solution on the NMR timescale. Meanwhile, the P–C coupling phenomenon can be detected as well in the 13 C NMR spectra and the coupling constants are highly consistent with that of reported bis(diethylamido)-1,3,5-trimethylpyrazol-4-ylthiophosphonate. In the 31 P NMR spectra, a singlet was observed at around 41 ppm for compounds **1a–1h** (Table 1).

The NMR spectra of 2a-2h mirrored those of 1a-1h. For example, the ¹H NMR spectra showed that the -NH signals were also observed as doublets at similar ppm values. In addition, the methyl groups were observed as singlets indicating the presence of highly symmetric pyrazole groups in 2a-2h in

PBr₂ + 2 H₂N-R THF, 2 Et₃N
$$r.t.$$
, overnight $r.t.$, overnight $r.t.$, overnight $r.t.$ overnight $r.$

Fig. 2 Synthesis and molecular structures of thiophosphinyl amide (1a-1h) and thiophosphonyl diamide (2a-2h).

Table 1 ¹H, ¹³C, ³¹P NMR and IR data of the compounds 1a-2h

	¹ H NMR (ppm)							¹³ C NMR (ppm) (<i>J</i> _{P-C} , Hz) 31 ₁	D	IR (cm ⁻¹)
	1- C <i>H</i> ₃	3- CH ₃	5- C <i>H</i> ₃	-N <i>H</i> (² <i>J</i> _{PH} , Hz)	1- <i>C</i> H ₃	3- <i>C</i> H ₃	5- <i>C</i> H ₃	NN	MR pm)	-NH
	3.63	2.18 2.26	1.94 2.00	, ,				144.08, 143.91 (25.5) 109.56, 108.54 (153.0) 148.73, 148.64 (13.5) 40 144.32, 144.14 (27.0) 109.35, 108.32 (154.5) 148.76, 148.68 (12.0) 41		3381 3385
	3.66 3.68	2.31 2.31	1.94 2.05	5.67, 5.65 (8.2)	36.43	13.93	11.41	144.17, 144.00 (25.5) 109.47, 108.44 (154.5) 148.71, 148.63 (12.0) 42 144.50, 144.33 (25.5) 109.45, 108.42 (154.5) 148.70, 148.61 (13.5) 41	.20	3386 3388
	3.67 3.63	2.34 2.32	2.04 2.09	, , ,				144.53, 144.36 (25.5) 109.16, 108.13 (154.5) 148.78, 148.70 (12.0) 41 144.61, 144.44 (25.5) 109.10, 108.07 (154.5) 148.80, 148.71 (13.5) 42		3382 3387
_	3.64	2.22 2.10		, , ,				$144.09,143.92(25.5)109.65,108.62(154.5)148.76,148.68(12.0)40\\144.60,144.43(25.5)109.58,108.56(153.0)149.27,149.18(13.5)40$		3373 3385
2b	3.70 3.68	2.28	1.97 1.95	5.09, 5.07 (6.6)	36.41	14.06	11.52	144.65, 144.49 (24.0) 108.79, 107.92 (130.5) 149.36, 149.28 (12.0) 29 144.70, 144.54 (24.0) 108.68, 107.82 (129.0) 149.34, 149.26 (12.0) 29	.97	3400 3402
2d	3.68	2.28	1.96	5.03, 5.01 (6.9)	36.41	14.06	11.56	144.69, 144.53 (24.0) 108.72, 107.85 (130.5) 149.31, 149.24 (12.0) 29 144.75, 144.59 (24.0) 108.65, 107.79 (129.0) 149.30, 149.22 (12.0) 30	.25	3402 3395
2f	3.70	2.31	1.96 1.96	4.93, 4.91 (7.2)	36.43	14.06	11.62	144.78, 144.62 (24.0) 108.64, 107.78 (129.0) 149.31, 149.23 (12.0) 30 144.84, 144.68 (24.0) 108.61, 107.75 (129.0) 149.30, 149.23 (10.5) 30	.71	3400 3401
_	3.67 3.69	2.28 2.20	1.95 1.84	, ,				144.65, 144.49 (24.0) 108.79, 107.92 (130.5) 149.36, 149.28 (12.0) 29 144.67, 144.51 (24.0) 108.89, 108.03 (129.0) 149.46, 149.39 (10.5) 29		3402 3402

Table 2 Nematicidal activity of 1a-1h, 2a-2h and bixafen towards M. incognita at 40 mg L^{-1}

Compound	Inhibition (%)	Compound	Inhibition (%)
1a	34.2 ± 1.2	2a	26.7 ± 1.0
1b	23.7 ± 1.6	2b	31.5 ± 1.8
1c	62.1 ± 0.8	2c	_
1d	24.8 ± 1.7	2d	_
1e	_	2e	37.3 ± 2.2
1f	_	2f	_
1g	_	2g	_
1h	_	2h	_
Bixafen	_		

solution on the NMR timescale. Compared with **1a–1h**, the single sharp –NH stretch absorption bands $\nu(\text{NH})$ of **2a–2h** were shifted to approximately 3400 cm⁻¹, a slightly higher wavenumber. The coupling constants in **2a–2h** are identify with that of in **1a–1h**, except for a slightly lower constants for P–C4, which was influenced by the variation of substitutes on the P atom. The singlets in the ³¹P NMR spectra were shifted downfield to approximately 30 ppm in **2a–2h** (Table 1).

The *in vitro* nematicidal activity was evaluated according to the classic protocol reported by Faske and Hurd.³⁰ After exploring a concentration of 40 mg L⁻¹ for 24 h, no obvious inhibitory activity could be detected for the lead compound bixafen towards *M. incognita*. In contrast, moderate nematicidal activities were observed for compounds **1a-1d**, **2a**, **2b** and **2e**, and particularly for **1c**, which had the highest inhibitory rate at 62.1%. Moreover, after treatment with **1c**, the activity of the surviving nematodes was highly inhibited. We thus demonstrated that modifying the basic structure scaffold present in the SDHI bixafen by incorporating an organophosphorus moiety was a successful approach for screening compounds

with encouraging nematicidal activity. Motivated by the above encouraging results, studies involving further modification of phosphorylated pyrazole derivatives and the evaluation of their nematicidal activity are currently underway.

Experimental

Materials and methods

All manipulations of air-sensitive materials were performed under rigorous exclusion of oxygen and moisture in Schlenktype glassware or on a dual manifold Schlenk line, interfaced with a high vacuum line. Tetrahydrofuran, toluene and triethylamine were predried using an MBraun solvent purification system (SPS-800) and then they were degassed, dried and stored over 4 Å molecular sieves. Starting materials 1 and 2 were synthesized following the previously published procedure.15 The other chemicals were purchased from commercial source and used without further purification. The ¹H, and ³¹P NMR spectra were recorded on a Bruker Avance II 300 MHz NMR spectrometer. 13C spectra were obtained from a Bruker Avance II 600 MHz NMR spectrometer. Chemical shifts for ¹H and ¹³C spectra are reported as parts per million (ppm) relative to tetramethylsilane and referenced to the residual ¹H or ¹³C resonances of the deuterated solvents. The 31P NMR data was referenced to H₃PO₄. IR spectra, from 4000 to 400 cm⁻¹, were obtained using a Nicolet IS10 FT-IR spectrometer equipped with a room temperature DLaTGS detector and a diamond ATR unit. Mass spectra (ESI) were recorded on a Bruker ultraflextreme MALDI-TOF instrument in positive ionization mode.

Synthesis of compounds 1a-1h

The corresponding primary amine (18.0 mmol) and Et_3N (1.822 g, 18.0 mmol) was dissolved in 100 mL dry THF. Then,

a THF solution of 1 (2.699 g, 9.0 mmol, in 20 mL dry THF) was added to the mixture previously cooled to 0 °C. After addition, the solution was slowly warmed to room temperature and was stirred overnight. Filtration was used to remove the formed white solid $\rm Et_3N \cdot HBr$. Then, $\rm S_8$ (0.288 g, 9.0 mmol) was added to the mixture and the mixture was further stirred for 6.0 h at 50 °C. After filtration, the violet filtrate was removed under vacuum and the residue was washed with 30 mL of petroleum ether, giving the crude product. The target compound could be further purified by crystallization using ethyl acetate/petroleum ether(v/v = 1:1).

N,N'-([1,1'-Biphenyl]-2-yl)-P-(1,3,5-trimethyl-1H-pyrazol-4-yl) phosphonothioic diamide (1a). White solid. Yield: 3.16 g, 68.9%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.47-7.00 (m, 18H, Ph), 5.42, 5.39 (d, 2H, ${}^{2}J_{PH} = 8.3$ Hz, NH), 3.63 (s, 3H, 1-CH₃), 2.18 (s, 3H, 3-CH₃), 1.94 (s, 3H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 : 148.69 (d, $J_{P-C} = 13.5$ Hz), 144.00 (d, $J_{P-C} = 25.5$ Hz), 138.63, 137.31, 132.27, 132.22, 130.75, 129.67, 129.56, 128.52, 128.39, 122.12, 118.07, 118.04, 109.01 (d, $J_{P-C} = 153.0 \text{ Hz}$), 36.36, 13.78, 11.27. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): δ = 40.4 ppm. IR (ATR, cm⁻¹): 3380, 3056, 3028, 1595, 1578, 1499, 1480, 1434, 1400, 1379, 1298, 1379, 1269, 1212, 1178, 1112, 1051, 1008, 994, 946, 931, 909, 838, 802, 754, 770, 736, 721, 704, 681, 643, 590, 549, 483, 473, 457. MS (ESI, pos.) m/z: found: $509.11 [M + H]^+$, calculated: 508.19. Anal. calcd for $C_{30}H_{29}N_4PS$ (508.62): C, 70.84; H, 5.75; N, 11.02; S, 6.30%; found: C, 70.67; H, 5.82; N, 10.89; S, 6.12%.

N,*N*′-(4′-Chloro-[1,1′-biphenyl]-2-yl)-*P*-(1,3,5-trimethyl-1*H*pyrazol-4-yl)phosphonothioic diamide (1b). White solid. Yield: 3.96 g, 76.1%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.44–7.02 (m, 16H, Ph), 5.28, 5.25 (d, 2H, ${}^{2}J_{PH} = 7.1$ Hz, NH), 3.66 (s, 3H, 1-CH₃), 2.26 (s, 3H, 3-CH₃), 2.00 (s, 3H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 148.72 (d, $J_{P-C} = 12.0$ Hz), 144.23 (d, $J_{P-C} =$ 27.0 Hz), 137.23, 137.13, 134.32, 131.29, 131.23, 131.15, 130.82, 129.65, 128.85, 122.47, 118.65, 118.62, 108.84 (d, $J_{P-C} = 154.5$ Hz), 36.44, 13.94, 11.44. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): $\delta = 41.3 \text{ ppm. IR (ATR, cm}^{-1}): 3385, 3357, 3029, 1607, 1591,$ 1579, 1500, 1479, 1449, 1397, 1381, 1295, 1283, 1272, 1205, 1179, 1160, 1101, 1084, 1051, 1018, 1007, 935, 917, 832, 801, 764, 693, 671, 651, 617, 595, 547, 502, 489, 470, 448. MS (ESI, pos.) m/z: found: 577.07 [M + H]⁺, calculated: 576.11. Anal. calcd for C₃₀H₂₇Cl₂N₄PS (577.51): C, 62.39; H, 4.71; N, 9.70; S, 5.55%; found: C, 62.11; H, 4.88; N, 9.83; S, 5.67%.

N,*N*'-(4'-Fluoro-[1,1'-biphenyl]-2-yl)-*P*-(1,3,5-trimethyl-1*H*-pyrazol-4-yl)phosphonothioic diamide (1c). White solid. Yield: 3.83 g, 78.0%. ¹H NMR (CD₃CN, 300 MHz, 298 K): 7.43–7.02 (m, 16H, Ph), 5.67, 5.65 (d, 2H, $^2J_{\rm PH}=8.2$ Hz, NH), 3.66 (s, 3H, 1-CH₃), 2.31 (s, 3H, 3-CH₃), 1.99 (s, 3H, 5-CH₃). ¹³C NMR (151 MHz, CD₂Cl₂, 298 K): 162.89 (d, $J_{\rm C-F}=247.6$ Hz), 148.67 (d, $J_{\rm P-C}=12.0$ Hz), 144.09 (d, $J_{\rm P-C}=25.5$ Hz), 137.41, 131.54 (d, $J_{\rm C-F}=7.6$ Hz), 131.34, 131.29, 130.94, 128.69, 122.29, 118.30 (d, $J_{\rm C-F}=7.6$ Hz), 116.44 (d, $J_{\rm C-F}=21.1$ Hz), 108.96 (d, $J_{\rm P-C}=154.5$ Hz), 36.43, 13.93, 11.41. ³¹P NMR (CD₃CN, 121.5 MHz, 298 K): δ = 41.8 ppm. IR (ATR, cm⁻¹): 3386, 3063, 3038, 2923, 1597, 1579, 1512, 1487, 1448, 1406, 1383, 1370, 1295, 1286, 1273, 1219, 1158, 1111, 1093, 1051, 1009, 940, 916, 839, 802, 766, 751, 710,

684, 673, 664, 639, 618, 601, 555, 546, 499, 487, 464, 435. MS (ESI, pos.) *m/z*: found: 545.13 [M + H]⁺, calculated: 544.17.

N,*N*′-(3′,4′-Difluoro-[1,1′-biphenyl]-2-yl)-*P*-(1,3,5-trimethyl-1H-pyrazol-4-yl)phosphonothioic diamide (1d). White solid. Yield: 4.11 g, 78.5%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.35-7.05 (m, 14H, Ph), 5.23, 5.21 (d, 2H, ${}^{2}J_{PH} = 6.5$ Hz, NH), 3.68 (s, 3H, 1-CH₃), 2.31 (s, 3H, 3-CH₃), 2.05 (s, 3H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 151.50 (dd, $I_{C-F} = 249.5$, 11.7 Hz), 149.84 (dd, $J_{C-F} = 251.5$, 12.1 Hz), 148.70 (d, $J_{P-C} = 13.5$ Hz), 144.42 (d, $J_{P-C} = 25.5$ Hz), 137.18, 135.66–135.60 (m), 130.91, 130.56, 130.50, 129.14, 126.13–126.07 (m), 122.63, 118.98 (d, *J*_C- $_{\rm F}$ = 18.1 Hz), 118.88, 118.85, 118.38 (d, $J_{\rm C-F}$ = 17.9 Hz), 108.94 (d, $J_{P-C} = 154.5 \text{ Hz}$), 36.44, 13.96, 11.50. ³¹P NMR (CD₂Cl₂, 121.5) MHz, 298 K): $\delta = 41.5$ ppm. IR (ATR, cm⁻¹):, 3389, 3030, 2925, 1604, 1579, 1515, 1491, 1453, 1410, 1383, 1311, 1279, 1261, 1228, 1212, 1181, 1160, 1116, 1107, 1052, 943, 922, 897, 874, 840, 821, 802, 768, 755, 708, 685, 674, 665, 634, 619, 586, 577, 546, 492, 450. MS (ESI, pos.) m/z: found: 581.08 [M + H]⁺, calculated: 580.15.

N,N'-(3',5'-Difluoro-[1,1'-biphenyl]-2-yl)-P-(1,3,5-trimethyl-1H-pyrazol-4-yl)phosphonothioic diamide (1e). White solid. Yield: 3.89 g, 74.4%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.37-6.85 (m, 14H, Ph), 5.25, 5.23 (d, 2H, ${}^{2}J_{PH} = 6.7$ Hz, NH), 3.67 (s, 3H, 1-CH₃), 2.34 (s, 3H, 3-CH₃), 2.04 (s, 3H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 163.71 (dd, $J_{C-F} = 250.7$, 12.1 Hz), 148.74 (d, $J_{P-C} = 12.0 \text{ Hz}$), 144.50 (d, $J_{P-C} = 25.5 \text{ Hz}$), 142.03 (t, $J_{\text{C-F}} = 9.7 \text{ Hz}$), 136.99, 130.61, 130.44, 130.40, 129.43, 122.71, 119.13, 112.88 (dd, $I_{C-F} = 20.4$, 4.5 Hz), 108.64 (d, $I_{P-C} = 154.5$ Hz), 103.81 (t, $J_{C-F} = 25.7$ Hz), 36.44, 14.00, 11.51. ³¹P NMR $(CD_2Cl_2, 121.5 \text{ MHz}, 298 \text{ K}): \delta = 41.9 \text{ ppm. IR (ATR, cm}^{-1}): 3382,$ 3056, 2976, 2928, 1601, 1577, 1500, 1482, 1436, 1422, 1406, 1381, 1364, 1295, 1275, 1211, 1178, 1160, 1113, 1073, 1050, 1009, 992, 915, 838, 795, 774, 757, 742, 731, 707, 692, 647, 622, 606, 587, 553, 538, 509, 489, 457. MS (ESI, pos.) m/z: found: 581.09 [M + H]⁺, calculated: 580.15.

N,N'-(3',4',5'-Trifluoro-[1,1'-biphenyl]-2-yl)-P-(1,3,5-trimethyl-1H-pyrazol-4-yl)phosphonothioic diamide (1f). White solid. Yield: 4.41 g, 79.4%. ¹H NMR (CD₃CN, 300 MHz, 298 K): 7.37–7.08 (m, 12H, Ph), 5.49, 5.47 (d, 2H, ${}^{2}J_{PH} = 6.7$ Hz, NH), 3.63 (s, 3H, 1-CH₃), 2.32 (s, 3H, 3-CH₃), 2.09 (s, 3H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 151.69 (ddd, $J_{C-F} = 252.2$, 10.1, 4.1 Hz), 148.76 (d, $J_{P-C} = 13.5$ Hz), 144.53 (d, $J_{P-C} = 25.5$ Hz), 139.93 (dt, $J_{C-F} = 253.7$, 16.6 Hz), 137.0, 134.78 (td, $J_{C-F} = 7.7$, 5.9 Hz), 130.81, 129.93, 129.88, 129.54, 122.92, 119.46, 119.43, 114.21 (dd, $J_{C-F} = 16.6$, 4.5 Hz), 108.63 (d, $J_{P-C} = 154.5$ Hz), 36.48, 14.13, 11.59. ³¹P NMR (CD₃CN, 121.5 MHz, 298 K): δ = 44.2 ppm. IR (ATR, cm⁻¹): 3387, 2950, 2923, 1606, 1590, 1580, 1515, 1497, 1476, 1451, 1408, 1381, 1363, 1296, 1272, 1199, 1175, 1113, 1098, 1083, 1048, 1016, 1006, 908, 835, 794, 762, 743, 692, 643, 609, 588, 541, 510, 495, 463, 426. MS (ESI, pos.) m/ z: found: $617.06 [M + H]^+$, calculated: 616.13.

N,*N*′-(4′-(benzyloxy)-[1,1′-biphenyl]-2-yl)-*P*-(1,3,5-trimethyl-1*H*-pyrazol-4-yl)phosphonothioic diamide (1g). White solid. Yield: 5.01 g, 77.2%. 1 H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.47–6.98 (m, 26H, Ph), 5.45, 5.42 (d, 2H, 2 J_{PH} = 8.9 Hz, NH), 5.11 (s, 4H, CH₂), 3.64 (s, 3H, 1-CH₃), 2.22 (s, 3H, 3-CH₃), 2.00 (s, 3H, 5-CH₃). 13 C NMR (151 MHz, CD₂Cl₂, 298 K): 159.00, 148.72 (d, *J*_{P-C}

= 12.0 Hz), 144.01 (d, $J_{\rm P-C}$ = 25.5 Hz), 137.56, 137.35, 131.90, 131.84, 130.96, 130.93, 128.97, 128.43, 128.28, 127.98, 122.05, 117.98, 117.95, 115.80, 109.12 (d, $J_{\rm P-C}$ = 154.5 Hz), 70.46, 36.41, 13.89, 11.36. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): δ = 41.3 ppm. IR (ATR, cm⁻¹): 3373, 3055, 3018, 2964, 2926, 1604, 1578, 1493, 1452, 1409, 1384, 1361, 1287, 1239, 1200, 1180, 1161, 1100, 1074, 1044, 1012, 992, 935, 918, 896, 858, 838, 760, 738, 725, 702, 691, 674, 644, 624, 615, 606, 585, 557, 503, 473, 463, 440. MS (ESI, pos.) m/z: found: 721.24 [M + H]⁺, calculated: 720.27. Anal. calcd for C₄₄H₄₁N₄O₂PS (720.87): C, 73.31; H, 5.73; N, 7.77; O, 4.44; S, 4.45%; found: C, 73.22; H, 5.95; N, 7.59; O, 4.30; S, 4.71%.

N,N'-(2-Benzylphenyl)-P-b(1,3,5-trimethyl-1H-pyrazol-4-yl) phosphonothioic diamide (1h). White solid. Yield: 3.72 g, 76.9%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.21–6.97 (m, 18H, Ph), 4.89, 4.86 (d, 2H, ${}^{2}J_{PH} = 8.0 \text{ Hz}$, NH), 3.86 (s, 4H, CH₂), 3.65 (s, 3H, 1-CH₃), 2.10 (s, 3H, 3-CH₃), 1.84 (s, 3H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 149.20 (d, $J_{P-C} = 13.5$ Hz), 144.52 (d, $J_{P-C} = 25.5 \text{ Hz}$, 139.14, 138.79, 131.59, 129.72, 129.67, 129.29, 128.78, 127.78, 127.13, 122.46, 119.55, 109.07 (d, $J_{P-C} = 153.0$ Hz), 38.92, 36.31, 13.75, 11.26. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): $\delta = 41.3$ ppm. IR (ATR, cm⁻¹): 3385, 3028, 2923, 1607, 1591, 1579, 1499, 1479, 1449, 1398, 1381, 1295, 1272, 1205, 1179, 1160, 1101, 1085, 1051, 1018, 1007, 935, 917, 865, 832, 801, 764, 693, 671, 651, 617, 596, 547, 489, 470, 448. MS (ESI, pos.) m/z: found: 537.18 [M + H]⁺, calculated: 536.22. Anal. calcd for C₃₂H₃₃N₄PS (536.68): C, 71.62; H, 6.20; N, 10.44; S, 5.97%; found: C, 71.47; H, 5.89; N, 10.55; S, 6.18%.

Synthesis of compounds 2a–2h. The corresponding primary amine (9.0 mmol) and $\rm Et_3N$ (0.911 g, 9.0 mmol) was dissolved in 100 mL dry toluene. Then, a toluene solution of 2 (2.963 g, 9.0 mmol, in 20 mL dry toluene) was added to the mixture and cooled to 0 °C. After addition, the mixture was slowly warmed to room temperature and was stirred overnight. The formed white solid $\rm Et_3N \cdot HBr$ was removed by filtration. Then, $\rm S_8$ (0.288 g, 9.0 mmol) was added to the mixture and it was stirred for another 6.0 h at 50 °C. After filtration, the filtrate was concentrated to approximately 20 mL. Then, 40 mL of petroleum ether was layered on top of the toluene solution. After one day, crystals of the target compound could be obtained at the border of the two layers.

N-([1,1'-Biphenyl]-2-yl)-P,P-bis(1,3,5-trimethyl-1H-pyrazol-4yl)phosphinothioic amide (2a). White solid. Yield: 1.90 g, 46.9%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.48-6.95 (m, 9H, Ph), 5.23, 5.20 (d, 1H, ${}^{2}J_{PH} = 7.7$ Hz, NH), 3.67 (s, 6H, 1-CH₃), 2.26 (s, 6H, 3-CH₃), 1.94 (s, 6H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 149.32 (d, $J_{P-C} = 12.0$ Hz), 144.57 (d, $J_{P-C} = 24.0$ Hz), 138.92, 137.92, 131.93, 131.88, 130.62, 129.83, 129.53, 128.31, 128.25, 121.30, 118.10, 118.06, 108.36 (d, $J_{P-C} = 130.5$ Hz), 36.36, 14.00, 11.44. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): $\delta = 29.6 \text{ ppm. IR (ATR, cm}^{-1}): 3400, 3037, 2934, 1601, 1577,$ 1516, 1491, 1443, 1407, 1381, 1362, 1312, 1287, 1262, 1230, 1214, 1179, 1112, 1051, 1014, 992, 922, 895, 838, 774, 752, 704, 687, 677, 645, 639, 609, 595, 586, 548, 508, 482, 459, 412. MS (ESI, pos.) m/z: found: 450.16 [M + H]⁺, calculated: 449.18. Anal. calcd for C₂₄H₂₈N₅PS (449.56): C, 64.12; H, 6.28; N, 15.58; S, 7.13%; found: C, 63.88; H, 5.95; N, 15.85; S, 7.52%.

N-(4'-Chloro-[1,1'-biphenyl]-2-yl)-P,P-bis(1,3,5-trimethyl-1Hpyrazol-4-yl)phosphinothioic amide (2b). White solid. Yield: 2.18 g, 50.1%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.42–6.98 (m, 8H, Ph), 5.09, 5.07 (d, 1H, ${}^{2}J_{PH} = 6.6$ Hz, NH), 3.68 (s, 6H, 1-CH₃), 2.28 (s, 6H, 3-CH₃), 1.95 (s, 6H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 149.30 (d, $I_{P-C} = 12.0 \text{ Hz}$), 144.62 (d, $I_{P-C} =$ 24.0 Hz), 137.92, 137.48, 134.26, 131.33, 130.69, 130.61, 130.56, 129.67, 128.58, 121.44, 118.41, 118.37, 108.25 (d, $J_{P-C} = 129.0$ Hz), 36.41, 14.06, 11.52. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): $\delta = 30.0$ ppm. IR (ATR, cm⁻¹): 3402, 3087, 3062, 3041, 2979, 2958, 2917, 1621, 1590, 1494, 1465, 1442, 1424, 1406, 1380, 1362, 1338, 1290, 1278, 1231, 1189, 1164, 1118, 1066, 1040, 1003, 982, 920, 885, 865, 844, 837, 753, 692, 677, 650, 638, 619, 606, 586, 577, 548, 540, 506, 463. MS (ESI, pos.) m/z: found: 484.13 $[M + H]^+$, calculated: 483.14. Anal. calcd for $C_{24}H_{27}$ -ClN₅PS (484.00): C, 59.56; H, 5.62; N, 14.47; S, 6.62%; found: C, 60.02; H, 5.86; N, 14.11; S, 6.98%.

N-(4'-Fluoro-[1,1'-biphenyl]-2-yl)-*P*,*P*-bis(1,3,5-trimethyl-1*H*-pyrazol-4-yl)phosphinothioic amide (2c). White solid. Yield: 2.21 g, 52.5%. 1 H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.35–6.95 (m, 8H, Ph), 5.09, 5.07 (d, 1H, 2 J_{PH} = 5.3 Hz, NH), 3.68 (s, 6H, 1-CH₃), 2.28 (s, 6H, 3-CH₃), 1.95 (s, 6H, 5-CH₃). 13 C NMR (151 MHz, CD₂Cl₂, 298 K): 162.85 (d, J_{C-F} = 247.6 Hz), 149.28 (d, J_{P-C} = 12.0 Hz), 144.61 (d, J_{P-C} = 24.0 Hz), 138.04, 134.94, 131.69 (d, J_{C-F} = 7.6 Hz), 130.80, 128.44, 121.36, 118.25 (d, J_{C-F} = 5.2 Hz), 116.43 (d, J_{C-F} = 21.1 Hz), 108.29 (d, J_{P-C} = 130.5 Hz), 36.40, 14.04, 11.51. 31 P NMR (CD₂Cl₂, 121.5 MHz, 298 K): δ = 29.9 ppm. IR (ATR, cm⁻¹): 3402, 3053, 3026, 2978, 2956, 2920, 1611, 1577, 1527, 1493, 1443, 1421, 1405, 1379, 1361, 1290, 1279, 1248, 1229, 1212, 1163, 1108, 1039, 992, 924, 884, 854, 837, 752, 691, 676, 647, 637, 606, 586, 549, 511, 496, 473. MS (ESI, pos.) *m/z*: found: 468.17 [M + H]⁺, calculated: 467.17.

N-(3',4'-Difluoro-[1,1'-biphenyl]-2-yl)-P,P-bis(1,3,5-trimethyl-1H-pyrazol-4-yl)phosphinothioic amide (2d). White solid. Yield: 2.37 g, 54.2%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.38-6.96 (m, 7H, Ph), 5.03, 5.01 (d, 1H, ${}^{2}J_{PH} = 5.9$ Hz, NH), 3.69 (s, 6H, 1-CH₃), 2.32 (s, 6H, 3-CH₃), 1.96 (s, 6H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 151.45 (dd, $J_{C-F} = 251.1$, 12.1 Hz), 149.85 $(dd, J_{C-F} = 249.7, 11.9 \text{ Hz}), 149.26 (d, J_{P-C} = 12.0 \text{ Hz}), 144.67 (d, J_{P-C} = 12.0 \text{ Hz}), 144.67 (d, J_{P-C} = 12.0 \text{ Hz})$ $J_{P-C} = 24.0 \text{ Hz}$), 137.94, 136.02 (dd, $J_{C-F} = 5.9$, 3.7 Hz), 130.72, 129.80, 129.75, 128.84, 126.30 (dd, $I_{C-F} = 6.2$, 3.4 Hz), 121.52, 119.45 (d, J_{C-F} = 16.6 Hz), 118.68, 118.64, 118.41 (d, J_{C-F} = 18.1 Hz), 108.2 (d, $J_{P-C} = 129.0$ Hz), 36.41, 14.06, 11.56. ³¹P NMR $(CD_2Cl_2, 121.5 \text{ MHz}, 298 \text{ K}): \delta = 30.3 \text{ ppm. IR (ATR, cm}^{-1}): 3395,$ 2928, 1598, 1575, 1510, 1492, 1443, 1422, 1402, 1381, 1360, 1294, 1275, 1224, 1158, 1111, 1093, 1050, 1006, 994, 914, 838, 817, 790, 759, 705, 686, 646, 610, 587, 559, 539, 509, 490, 472, 421. MS (ESI, pos.) m/z: found: 468.13 [M + H]⁺, calculated: 485.16.

N-(3′,5′-Difluoro-[1,1′-biphenyl]-2-yl)-*P*,*P*-bis(1,3,5-trimethyl-1*H*-pyrazol-4-yl)phosphinothioic amide (2e). White solid. Yield: 2.45 g, 53.9%. 1 H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.39–6.82 (m, 7H, Ph), 5.05, 5.02 (d, 1H, 2 $J_{\rm PH} = 7.3$ Hz, NH), 3.69 (s, 6H, 1-CH₃), 2.33 (s, 6H, 3-CH₃), 1.96 (s, 6H, 5-CH₃). 13 C NMR (151 MHz, CD₂Cl₂, 298 K): 163.68 (dd, $J_{\rm C-F} = 249.9$, 12.1 Hz), 149.27 (d, $J_{\rm P-C} = 12.0$ Hz), 144.70 (d, $J_{\rm P-C} = 24.0$ Hz), 142.36 (t, $J_{\rm C-F} = 9.5$

Paper

Hz), 137.75, 130.40, 129.64, 129.59, 129.08, 121.60, 118.92, 118.88, 113.01 (dd, $J_{\text{C-F}} = 20.1$, 4.5 Hz), 108.21 (d, $J_{\text{P-C}} = 129.0$ Hz), 103.70 (t, $J_{\text{C-F}} = 24.2$ Hz), 36.39, 14.02, 11.56. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): $\delta = 30.5$ ppm. IR (ATR, cm⁻¹): 3400, 3037, 2934, 1600, 1577, 1516, 1491, 1443, 1408, 1380, 1362, 1312, 1286, 1262, 1230, 1213, 1179, 1111, 1050, 1014, 992, 923, 895, 837, 774, 752, 704, 689, 644, 609, 583, 548, 507, 482, 459, 419. MS (ESI, pos.) m/z: found: 486.12 [M + H]⁺, calculated: 485.16.

N-(3',4',5'-Trifluoro-[1,1'-biphenyl]-2-yl)-P,P-bis(1,3,5-trimethyl-1H-pyrazol-4-yl)phosphinothioic amide (2f). White solid. Yield: 2.17 g, 47.8%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.39-6.95 (m, 6H, Ph), 4.94, 4.91 (d, 1H, 2JPH = 7.2 Hz, NH), 3.69 (s, 6H, 1-CH₃), 2.35 (s, 6H, 3-CH₃), 1.96 (s, 6H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 151.79 (ddd, $J_{C-F} = 249.2$, 12.1, 4.7 Hz), 149.27 (d, $J_{P-C} = 10.5$ Hz), 144.76 (d, $J_{P-C} = 24.0$ Hz), 139.80 (dt, $J_{P-C} = 252.2$, 15.6 Hz), 137.82, 135.15 (td, $J_{C-F} = 8.1$, 6.1 Hz), 135.15, 130.59, 129.23, 128.94, 121.73, 119.18, 119.14, 114.33 (dd, $J_{C-F} = 16.2$, 4.5 Hz), 108.18 (d, $J_{P-C} = 129.0$ Hz), 36.43, 14.06, 11.62. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): δ = 30.7 ppm. IR (ATR, cm⁻¹): 3401, 3037, 2977, 2955, 1600, 1577, 1516, 1491, 1443, 1407, 1380, 1362, 1312, 1287, 1262, 1230, 1214, 1179, 1112, 1051, 1015, 992, 922, 895, 858, 774, 752, 705, 687, 677, 645, 638, 609, 595, 589, 548, 507, 482, 459, 438, 419. MS (ESI, pos.) m/z: found: 504.14 [M + H]+, calculated: 503.15.

N-(4'-(benzyloxy)-[1,1'-biphenyl]-2-yl)-P,P-bis(1,3,5-trimethyl-1H-pyrazol-4-yl)phosphinothioic amide (2g). White solid. Yield: 2.51 g, 50.1%. ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.45–6.95 (m, 13H, Ph), 5.24, 5.22 (d, 1H, ${}^{2}J_{PH} = 6.8 \text{ Hz}$, NH), 5.09 (s, 2H, CH₂), 3.67 (s, 6H, 1-CH₃), 2.28 (s, 6H, 3-CH₃), 1.95 (s, 6H, 5-CH₃). ¹³C NMR (151 MHz, CD_2Cl_2 , 298 K): 158.92, 149.32 (d, $J_{P-C} = 12.0$ Hz), 144.57 (d, $J_{P-C} = 24.0 \text{ Hz}$), 138.15, 137.31, 131.51, 131.46, 131.24, 131.02, 130.84, 128.95, 128.42, 128.00, 127.95, 121.23, 117.99, 117.95, 115.76, 108.36 (d, $J_{P-C} = 130.5 \text{ Hz}$), 70.43, 36.38, 14.04, 11.49. ³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): δ = 29.6 ppm. IR (ATR, cm⁻¹): 3402, 3053, 3027, 2978, 2956, 2934, 1611, 1577, 1527, 1493, 1443, 1421, 1405, 1380, 1361, 1291, 1279, 1248, 1230, 1213, 1163, 1108, 1040, 992, 924, 884, 854, 838, 752, 715, 691, 677, 648, 647, 606, 586, 549, 540, 511, 497, 473, 418. MS (ESI, pos.) m/z: found: 556.19 [M + H]⁺, calculated: 555.22. Anal. calcd for $C_{31}H_{34}N_5OPS$ (555.68): C, 67.01; H, 6.17; N, 12.60; O, 2.88; S, 5.77%; found: C, 67.46; H, 6.32; N, 12.33; S, 6.59%.

N-(2-Benzylphenyl)-*P*,*P*-bis(1,3,5-trimethyl-1*H*-pyrazol-4-yl) phosphinothioic amide (2h). White solid. Yield: 1.98 g, 47.3%.
¹H NMR (CD₂Cl₂, 300 MHz, 298 K): 7.29–6.91 (m, 9H, Ph), 4.78, 4.75 (d, 1H, $^2J_{\rm PH}$ = 7.3 Hz, NH), 3.92 (s, 2H, CH₂), 3.68 (s, 6H, 1-CH₃), 2.20 (s, 6H, 3-CH₃), 1.84 (s, 6H, 5-CH₃).
¹³C NMR (151 MHz, CD₂Cl₂, 298 K): 149.43 (d, $J_{\rm P-C}$ = 10.5 Hz), 144.59 (d, $J_{\rm P-C}$ = 24.0 Hz), 139.40, 139.20, 131.62, 129.26, 128.77, 128.62, 128.57, 127.52, 127.17, 121.55, 119.14, 119.10, 108.46 (d, $J_{\rm P-C}$ = 129.0 Hz), 39.09, 36.34, 13.90, 11.46.
³¹P NMR (CD₂Cl₂, 121.5 MHz, 298 K): δ = 29.1 ppm. IR (ATR, cm⁻¹): 3402, 3087, 3062, 3036, 2978, 2957, 2917, 1621, 1590, 1494, 1465, 1442, 1424, 1406, 1380, 1362, 1338, 1290, 1278, 1231, 1189, 1164, 1118, 1066, 1040, 1003, 982, 921, 885, 864, 844, 837, 752, 692, 677, 650, 638, 619, 606, 586, 548, 540, 506, 463. MS (ESI, pos.) *m/z*: found:

464.17 $[M + H]^+$, calculated: 463.20. Anal. calcd for $C_{25}H_{30}N_5PS$ (463.58): C, 64.77; H, 6.52; N, 15.11; S, 6.92%; found: C, 64.98; H, 6.89; N, 15.49; S, 7.32%.

Nematicidal activity. The nematicidal activities of the synthesized compounds were determined at the China Agricultural University following the published procedure. 30,38 Pure compounds 1a-2h and bixafen were initially dissolved in 0.5 mL of DMSO, and were further diluted with distilled water to 1.0 L to obtain 80 mg L^{-1} dilutions for bioassays. Thus, the final concentration of DMSO was less than 1% v/v. The nematodes M. incognita used in experiments were originally isolated from tomato plants. M. incognita eggs were extracted using the NaClO (0.5%, 3 min) procedure described by Hussey and Barker³⁹ and second-stage juveniles (J2) were hatched over 2-3 days in Baermann funnels at 26 °C. All I2s hatched in the first 3 days were discarded and a further 24 h was allowed to elapse before I2 nematodes were collected for use in these experiments. Bixafen at a concentration of 80 mg L^{-1} served as a positive control. The negative control was carried out by following the same experimental procedure in the absence of the tested compounds. Solutions of test compounds (0.5 mL) and approximately 50 M. incognita J2s in 0.5 mL of water were mixed and plated in 24-well plates. The plates were then wrapped in parafilm and stored in the dark at 26 °C for 24 h. The nematodes were considered immotile if they did not respond to being touched by a small probe under an inverted microscope. Moreover, the percentage of immotile nematodes was calculated for each compound and the results are listed in Table 2.

Conclusions

A series of thiophosphinyl amide and thiophosphonyl diamide compounds were synthesized and purified by facile purification methods and characterized by standard spectroscopic/analytic techniques. Our preliminary nematicidal activity investigation shows that some compounds manifested higher nematicidal activity than the lead compound bixafen. Hence, the modification of SDHI by the incorporation of an organothiophosphorus group could be a successful approach for the synthesis of nematicidal compounds with improved activities.

Conflicts of interest

The authors have no conflicts to declare.

Acknowledgements

We acknowledge China Agricultural University for the nematicidal activity determination of our compounds.

References

- 1 S. Demkowicz, J. Rachon, M. Daśko and W. Kozak, *RSC Adv.*, 2016, **6**, 7101–7112.
- 2 H. Yu, H. Yang, E. Shi and W. Tang, *Med. Drug Discovery*, 2020, **8**, 100063.

- 3 J. B. Rodriguez and C. Gallo-Rodriguez, *ChemMedChem*, 2019, 14, 190-216.
- 4 C. Schultz, Bioorg. Med. Chem., 2003, 11, 885-898.
- 5 J. Grein, N. Ohmagari, D. Shin, G. Diaz, E. Asperges, A. Castagna, T. Feldt, G. Green, M. L. Green, F.-X. Lescure, R. Oda, K. Yo, E. Quiros-Roldan, Nicastri. Α. Studemeister, J. Redinski, S. Ahmed, J. Bernett, Chelliah, D. Chen, S. Chihara, S. H. Cohen, J. Cunningham, A. D'Arminio Monforte, S. Ismail, H. Kato, G. Lapadula, E. L'Her, T. Maeno, S. Majumder, M. Massari, M. Mora-Rillo, Y. Mutoh, D. Nguyen, E. Verweij, A. Zoufaly, O. Osinusi, A. DeZure, Y. Zhao, L. Zhong, A. Chokkalingam, E. Elboudwarej, L. Telep, L. Timbs, I. Henne, S. Sellers, H. Cao, S. K. Tan, L. Winterbourne, P. Desai, R. Mera, A. Gaggar, R. P. Myers, D. M. Brainard, R. Childs and T. Flanigan, N. Engl. J. Med., 2020, 382, 2327-2336.
- 6 M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong and G. Xiao, *Cell Res.*, 2020, 30, 269–271.
- 7 L. G. Costa, Toxicol. Sci., 2017, 162, 24-35.
- 8 S. Wada, K. Toyota and A. Takada, J. Nematol., 2011, 43, 1–6.
- 9 S. Wada and K. Toyota, *Microbes Environ.*, 2008, 23, 331-336.
- 10 G. Georgiadis, C. Mavridis, C. Belantis, I. E. Zisis, I. Skamagkas, I. Fragkiadoulaki, I. Heretis, V. Tzortzis, K. Psathakis, A. Tsatsakis and C. Mamoulakis, *Toxicology*, 2018, 406-407, 129-136.
- 11 M. Eddleston, N. A. Buckley, P. Eyer and A. H. Dawson, *Lancet*, 2008, **371**, 597–607.
- 12 M. Jokanovic, Toxicology, 2001, 166, 139-160.
- 13 F. Worek, H. Thiermann and T. Wille, Arch. Toxicol., 2020, 94, 2275–2292.
- 14 A. Ben Akacha, N. Ayed, B. Baccar and C. Charrier, *Phosphorus, Sulfur Silicon Relat. Elem.*, 1988, **40**, 63–68.
- 15 A. A. Tolmachev, A. I. Sviridon, A. N. Kostyuk and A. M. Pinchuk, *Heteroat. Chem.*, 1995, **6**, 449–459.
- 16 A. A. Tolmachev, S. P. Ivonin and A. M. Pinchuk, *Heteroat. Chem.*, 1995, 6, 407–412.
- 17 N. S. Goulioukina, N. N. Makukhin, E. D. Shinkarev, Y. K. Grishin, V. A. Roznyatovsky and I. P. Beletskaya, *Org. Biomol. Chem.*, 2016, 14, 10000–10010.
- 18 S. Fischer, J. Hoyano and L. K. Peterson, *Can. J. Chem.*, 1976, 54, 2710–2714.
- 19 J. Zhang, M. Wenzel, K. Schnaars, F. Hennersdorf, K. Schwedtmann, J. Maerz, A. Rossberg, P. Kaden,

- F. Kraus, T. Stumpf and J. J. Weigand, *Dalton Trans.*, 2021, **50**, 3550–3558.
- 20 M. Eddleston, *Annu. Rev. Pharmacol. Toxicol.*, 2019, **59**, 341–360.
- 21 S. G. Kucukguzel and S. Senkardes, Eur. J. Med. Chem., 2015, 97, 786–815.
- 22 J. Elguero, P. Goya, N. Jagerovic and A. M. S. Silva, *Targets Heterocycl. Syst.*, 2002, **6**, 52–98.
- 23 A. Ansari, A. Ali, M. Asif and Shamsuzzaman, *New J. Chem.*, 2017, 41, 16–41.
- 24 M. F. Khan, M. M. Alam, G. Verma, W. Akhtar, M. Akhter and M. Shaquiquzzaman, *Eur. J. Med. Chem.*, 2016, **120**, 170–201.
- 25 N. Sudhapriya, C. Balachandran, S. Awale and P. T. Perumal, *New J. Chem.*, 2017, **41**, 5582–5594.
- 26 J.-M. Kee, R. C. Oslund, A. D. Couvillon and T. W. Muir, *Org. Lett.*, 2015, 17, 187–189.
- S. A.-G. Abdel-Aziz, T. El-Sayed Ali, K. M. El-Mahdy and S. M. Abdel-Karim, *Eur. J. Chem.*, 2011, 2, 25–35.
- 28 S. K. Nayab Rasool, C. Subramanyam, D. B. Janakiramudu, P. Supraja, R. Usha and C. N. Raju, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2018, 193, 470-474.
- 29 S. K. Thaslim Basha, D. Subba Rao, G. Madhava, S. T. Basha, M. N. Devamma, M. S. Saddala, U. R. Asupatri and C. N. Raju, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2015, 190, 1064–1074.
- 30 T. R. Faske and K. Hurd, J. Nematol., 2015, 47, 316-321.
- 31 N. Umetsu and Y. Shirai, J. Pestic. Sci., 2020, 45, 54-74.
- 32 G. Li, K. Zhang, J. Xu, J. Dong and Y. Liu, *Recent Pat. Biotechnol.*, 2007, **1**, 212–233.
- 33 J. Chen, Q. X. Li and B. Song, *J. Agric. Food Chem.*, 2020, **68**, 12175–12188.
- 34 N. Sugimoto, A. Takahashi, R. Ihara, Y. Itoh, A. Jouraku, T. Van Leeuwen and M. Osakabe, *Insect Biochem. Mol. Biol.*, 2020, **123**, 103410.
- 35 T. Furuya, K. Machiya, S. Fujioka, M. Nakano and K. Inagaki, J. Pestic. Sci., 2017, 42, 132–136.
- 36 S. P. Ivonin, T. E. Terikovska, A. A. Chaikovskaya, A. P. Marchenko, G. N. Koydan, A. M. Pinchuk and A. A. Tolmachev, *Heteroat. Chem.*, 1999, 10, 213–221.
- 37 A. A. Chaikovskaya, Y. V. Dmitriv, S. P. Ivonin, A. M. Pinchuk and A. A. Tolmachev, *Heteroat. Chem.*, 2005, **16**, 599–604.
- 38 X. Ji, J. Li, B. Dong, H. Zhang, S. Zhang and K. Qiao, *Crop Protect.*, 2019, **122**, 84–89.
- 39 R. S. Hussey and K. R. Barker, *Plant Dis. Rep.*, 1973, **57**, 1025–1028.